Aminah Jatoi, MD, of the Mayo Clinic (IMAGE)

Alliance for Clinical Trials in Oncology

Aminah Jatoi, MD, of the Mayo Clinic

Caption

Alliance A222004: Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Headed by Aminah Jatoi, MD, of the Mayo Clinic, this phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with advanced cancer, including colorectal cancer, that has spread to other places in the body. This study aims to find out if olanzapine is better than the usual approach for stimulating appetite and preventing weight loss in people with advanced cancers. The primary outcome of the study is to find out which medication is more effective helping people in the study gain weight. 

Credit

Mayo Clinic

Usage Restrictions

none

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.